As the healthcare landscape continues to change, with clinical trials, regulatory issues, and reimbursement evolving with new ideas, life sciences companies must adjust their go-to-market strategy. To gain the best advantage for the company and the product, that might involve launching outside of the country first. Biocom has asked three companies to discuss how they evaluated their options and why they selected a particular strategy for commercialization. More information and online registration is here.